OKYO Pharma Ltd. (OKYO), on Monday, said it has appointed Robert Dempsey as Chief Executive Officer, effective immediately.
Robert Dempsey will take over from Gary Jacob, who has transitioned to the role of chief development officer and will continue to serve as a board member.
The company said Dempsey brings more than two decades of global ophthalmology experience spanning drug development, commercialization and strategic transactions.
Dempsey previously served as group vice president and head of global ophthalmology at Shire.
The company said the leadership change is intended to support the next phase of growth, with a focus on advancing its lead asset, urcosimod, for the treatment of neuropathic corneal pain and other ocular inflammatory diseases.
On Friday, OKYO Pharma closed trading 7.21% higher at $2.2300 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.